The US FDA Fast Track status advances remlifanserin for Alzheimer disease psychosis, with phase 2 RADIANT data expected in fall 2026.
The FDA has granted Fast Track designation to remlifanserin (ACP-204), an investigational serotonin 5-HT2A receptor inverse agonist, for hallucinations and delusions associated with
“FDA Fast Track designation for remlifanserin underscores the significant unmet need for new treatment options for people living with Alzheimer’s disease psychosis,” Catherine Owen Adams, chief executive officer of Acadia, said in a statement.¹ No therapies are currently approved by the FDA specifically for Alzheimer disease psychosis, according to the company.
The regulatory update coincides with completion of enrollment in the phase 2 portion of RADIANT, Acadia’s clinical development program evaluating remlifanserin for hallucinations and delusions associated with Alzheimer disease psychosis. Topline phase 2 results are expected between September and October 2026.¹
Acadia described RADIANT as having an “operationally seamless” design, with screening and enrollment already underway in phase 3 studies. However, the announcement did not provide the phase 2 sample size, treatment duration, comparator, dosing regimen, primary or secondary end points, statistical analysis plan, or participant eligibility criteria. It also did not report any efficacy or safety results.
These omissions limit interpretation of the program until topline findings—and ultimately complete peer-reviewed data—become available. The decision to begin phase 3 enrollment before disclosure of phase 2 results may accelerate development timelines, but the clinical implications will depend on whether the forthcoming data demonstrate a meaningful reduction in psychotic symptoms with acceptable tolerability.
Remlifanserin is designed to act as a potent, highly selective inverse agonist at the 5-HT2A receptor. Acadia is developing the agent for psychosis associated with Alzheimer disease and Lewy body disease. The proposed therapeutic rationale is that selective 5-HT2A inverse agonism may modulate pyramidal-cell excitability and restore excitatory-inhibitory balance without directly blocking dopamine D2 receptors.¹,²
This pharmacologic approach could be relevant because dopamine receptor blockade is associated with several tolerability concerns encountered with atypical antipsychotic treatment. Nevertheless, the assertion that remlifanserin may avoid those concerns remains a hypothesis requiring confirmation in adequately powered clinical trials. The available evidence cited by Acadia includes a review of 5-HT2A receptor modulation in dementia-related psychosis and nonclinical ACP-204 findings presented as a conference poster.²,³ Neither source establishes clinical benefit in patients.
Fast Track status is intended for investigational therapies addressing serious conditions and unmet medical needs. It can provide opportunities for more frequent communication with the FDA and, when applicable, consideration for expedited review mechanisms.¹ The designation does not indicate that the FDA has concluded remlifanserin is superior to available management approaches.
The next clinically consequential update will be the RADIANT phase 2 readout. Important questions include the magnitude and durability of symptom improvement, rates of discontinuation and serious adverse events, and whether outcomes differ by
